Frew Sarah E, Kettler Hannah E, Singer Peter A
McLaughlin-Rotman Centre for Global Health, University Health Network and University of Toronto, in Ontario, Canada.
Health Aff (Millwood). 2008 Jul-Aug;27(4):1029-41. doi: 10.1377/hlthaff.27.4.1029.
India and China have made major progress toward establishing research- and innovation-based health biotechnology sectors. Local health needs, including diseases that predominantly affect the poor, have driven much of this success. We argue that emerging domestic firms can play an important role as reliable and high-quality suppliers of existing products and as innovators for global health needs. Indeed, these firms' participation may make existing global health approaches more sustainable. However, global health stakeholders, including international donors and the Indian and Chinese governments, will need to fashion incentives for these companies to retain a strategic focus on the global poor.
印度和中国在建立基于研究与创新的健康生物技术领域方面取得了重大进展。包括主要影响贫困人口的疾病在内的当地健康需求推动了这一成功的很大一部分。我们认为,新兴的本土企业可以作为现有产品可靠且高质量的供应商,以及全球健康需求的创新者发挥重要作用。事实上,这些企业的参与可能会使现有的全球健康方法更具可持续性。然而,包括国际捐助者以及印度和中国政府在内的全球健康利益相关者,将需要制定激励措施,促使这些公司在战略上继续关注全球贫困人口。